These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 23176332)
21. New imaging techniques for more effective treatment in glioblastoma. Fay MF; Martin JH; Rose S Intern Med J; 2014 Jan; 44(1):5-6. PubMed ID: 24450518 [No Abstract] [Full Text] [Related]
22. Case report on a patient with neurofibromatosis type 1 and a frontal cystic glioblastoma. Hakan T; Aker FV Neurol Neurochir Pol; 2008; 42(4):362-5. PubMed ID: 18975243 [TBL] [Abstract][Full Text] [Related]
27. What next for newly diagnosed glioblastoma? Domingo-Musibay E; Galanis E Future Oncol; 2015; 11(24):3273-83. PubMed ID: 26558493 [TBL] [Abstract][Full Text] [Related]
28. Neuroimaging: diagnosis and response assessment in glioblastoma. Clarke JL; Chang SM Cancer J; 2012; 18(1):26-31. PubMed ID: 22290254 [TBL] [Abstract][Full Text] [Related]
29. [Future of diagnostic radiology: prediction of treatment outcome using MRI]. Hatakenaka M; Yoshiura T; Shioyama Y; Honda H Fukuoka Igaku Zasshi; 2010 Mar; 101(3):41-5. PubMed ID: 20653196 [No Abstract] [Full Text] [Related]
30. High grade astrocytomas in children: Hartford Hospital experience. Hall AJ; Wagle VG; Voytek T Conn Med; 1991 Mar; 55(3):135-8. PubMed ID: 1647288 [TBL] [Abstract][Full Text] [Related]
31. Glioblastoma care in the elderly. Jordan JT; Gerstner ER; Batchelor TT; Cahill DP; Plotkin SR Cancer; 2016 Jan; 122(2):189-97. PubMed ID: 26618888 [TBL] [Abstract][Full Text] [Related]
32. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients? Van Gool S; De Vleeschouwer S Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731 [No Abstract] [Full Text] [Related]
33. Introduction: Glioblastoma: an update on pathophysiology and management strategies. Berger MS; Bruce JN; Chen TC; Zadeh G Neurosurg Focus; 2014 Dec; 37(6):Introduction. PubMed ID: 25434392 [No Abstract] [Full Text] [Related]
34. The imaging core lab perspective on glioblastoma imaging and response assessment in clinical trials. Goldmacher GV; Raunig D Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii48-50. PubMed ID: 25313238 [TBL] [Abstract][Full Text] [Related]
35. Reply to: age as a predictive factor in glioblastomas: population-based study. Mikheev AM; Horner PJ; Ramakrishna R; Maxwell JP; Stoll EA; Rostomily RC Neuroepidemiology; 2010; 34(2):130. PubMed ID: 20068359 [No Abstract] [Full Text] [Related]
36. Neuroimaging and genetic influence in treating brain neoplasms. Hygino da Cruz LC; Kimura M Neuroimaging Clin N Am; 2015 Feb; 25(1):121-40. PubMed ID: 25476517 [TBL] [Abstract][Full Text] [Related]
37. Role of nanobiotechnology in the personalized management of glioblastoma multiforme. Jain KK Nanomedicine (Lond); 2011 Apr; 6(3):411-4. PubMed ID: 21542679 [No Abstract] [Full Text] [Related]
39. Glioblastoma: background, standard treatment paradigms, and supportive care considerations. Ellor SV; Pagano-Young TA; Avgeropoulos NG J Law Med Ethics; 2014; 42(2):171-82. PubMed ID: 25040381 [TBL] [Abstract][Full Text] [Related]
40. Remitting signs in cerebral mass lesions. Fincham RW; Worrell JB Am Fam Physician; 1973 Jun; 7(6):96-100. PubMed ID: 4350680 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]